领航医药生物科技（00399）公布截至2023年9月30日止6个月业绩，收益372.7万港元，同比减少9.93%；公司拥有人应占溢利约1.94亿港元，去年同期应占亏损约1.16亿港元；基本每股盈利13.23港仙。
领航医药生物科技公布中期业绩 拥有人应占溢利约1.94亿港元
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.